Anti-Human CD14 Recombinant Nanobody (SAA2077) is a recombinant nanobody targeting Human CD14 (clone SAA2077). Format: VHH-8His-Cys-tag (alpaca host). Reactivity: Human. Supplied as a liquid in 0.01M PBS, pH 7.4. Applications: ELISA. Purity: >95% as determined by SDS-PAGE. For research use only.
Monocyte differentiation antigen CD14 is a ~40 kDa protein. Coreceptor for bacterial lipopolysaccharide. In concert with LBP, binds to monomeric lipopolysaccharide and delivers it to the LY96/TLR4 complex, thereby mediating the innate immune response to bacterial lipopolysaccharide (LPS). Acts via MyD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Acts as a coreceptor for TLR2:TLR6 heterodimer in response to diacylated lipopeptides and for TLR2:TLR1 heterodimer in response to triacylated lipopeptides, these clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway. Binds electronegative LDL (LDL(-)) and mediates the cytokine release induced by LDL(-).
Product Name:
Anti-Human CD14 Recombinant Nanobody (SAA2077)
Size:
50 µg, 100 µg, 1 mg
Product SKU:
GXRM03821
Target:
CD14
Host Species:
Alpaca
Antibody Type:
Monoclonal
Clone ID:
SAA2077
Reactivity:
Human
Buffer:
0.01M PBS pH 7.4.
Storage & Shipping:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
